Valuation: IXICO plc

Market Cap 1.8Cr 2.4Cr 2.1Cr 1.93Cr 3.41Cr 228.72Cr 3.46Cr 23Cr 9.01Cr 112.43Cr 9.02Cr 8.82Cr 387.43Cr P/E 2026 *
-5.16x
P/E 2027 * -6.35x
Enterprise Value 83.89L 1.12Cr 97.93L 90L 1.59Cr 106.66Cr 1.62Cr 11Cr 4.2Cr 52Cr 4.2Cr 4.11Cr 180.67Cr EV / Sales 2026 *
1.12x
EV / Sales 2027 * 1.37x
Free-Float
89.25%
Yield 2026 *
-
Yield 2027 * -
3 years 0.07
Extreme 0.07
0.15
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 21/08/2019
Director/Board Member 60 21/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
-53.33%-.--% - - 2.4Cr
+1.70%+7.41%+3.12%+8.46% 4.99TCr
+0.92%+3.93%+399.71%+605.33% 4.02TCr
+1.89%+8.32%+26.06%-6.35% 3.46TCr
+2.38%+6.35%+21.25%+64.58% 3.31TCr
+3.96%+10.67%+11.89%+38.86% 2.75TCr
+2.51%+5.27% - - 1.7TCr
+2.58%+5.79%+73.44%+133.27% 1.59TCr
+0.32%+0.58%+13.67%+19.09% 1.39TCr
+3.30%+0.76%+90.23%+99.12% 1.35TCr
Average -3.38%+5.82%+79.92%+120.30% 2.73TCr
Weighted average by Cap. +2.06%+6.53%+90.75%+137.74%

Financials

2026 *2027 *
Net sales 75L 1Cr 87.55L 80.46L 1.42Cr 95Cr 1.44Cr 9.66Cr 3.76Cr 47Cr 3.76Cr 3.68Cr 161.53Cr 90L 1.2Cr 1.05Cr 96.55L 1.71Cr 114.43Cr 1.73Cr 12Cr 4.51Cr 56Cr 4.51Cr 4.41Cr 193.83Cr
Net income -24L -32.05L -28.02L -25.75L -45.52L -31Cr -46.21L -3.09Cr -1.2Cr -15Cr -1.2Cr -1.18Cr -52Cr -28L -37.39L -32.69L -30.04L -53.11L -36Cr -53.91L -3.61Cr -1.4Cr -17Cr -1.4Cr -1.37Cr -60Cr
Net Debt -96L -1.28Cr -1.12Cr -1.03Cr -1.82Cr -122.06Cr -1.85Cr -12Cr -4.81Cr -60Cr -4.81Cr -4.71Cr -206.75Cr -57L -76.12L -66.54L -61.15L -1.08Cr -72Cr -1.1Cr -7.34Cr -2.85Cr -36Cr -2.86Cr -2.8Cr -122.76Cr
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0825GBP
Average target price
0.2600GBP
Spread / Average Target
+215.15%

Annual profits - Rate of surprise